Ruxolitinib is effective in the treatment of a patient with refractory T-ALL.
Journal
EJHaem
ISSN: 2688-6146
Titre abrégé: EJHaem
Pays: United States
ID NLM: 101761942
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
27
10
2020
revised:
10
11
2020
accepted:
12
11
2020
entrez:
18
7
2022
pubmed:
4
12
2020
medline:
4
12
2020
Statut:
epublish
Résumé
T-cell acute lymphoblastic leukemia (T-ALL) is a rare, aggressive T-cell malignancy. Chemotherapy alone cures only 25-45% of the cases, thus, novel treatment agents and strategies are urgently needed. We assessed the efficacy of ruxolitinib in a patient with a cutaneous relapse after allogeneic blood cell transplantation of a refractory T-ALL with a Janus kinase 3 (
Identifiants
pubmed: 35846099
doi: 10.1002/jha2.143
pii: JHA2143
pmc: PMC9175749
doi:
Types de publication
Journal Article
Langues
eng
Pagination
139-142Informations de copyright
© 2020 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest.
Références
Blood. 2015 Mar 12;125(11):1759-67
pubmed: 25645356
Blood. 2014 Nov 13;124(20):3092-100
pubmed: 25193870
Blood. 1994 Sep 1;84(5):1603-12
pubmed: 8068949
Chem Biol. 2011 Mar 25;18(3):314-23
pubmed: 21439476
Blood. 2017 Mar 2;129(9):1113-1123
pubmed: 28115373
Leukemia. 2015 Dec;29(12):2427-9
pubmed: 26449659
Nature. 2007 Apr 12;446(7137):758-64
pubmed: 17344859
Blood. 2018 Jan 25;131(4):421-425
pubmed: 29187379
J Biol Chem. 2015 Nov 27;290(48):29022-34
pubmed: 26446793
Hemasphere. 2019 Oct 22;3(6):e313
pubmed: 31976485
Blood. 2007 Feb 1;109(3):910-5
pubmed: 17023577
Leuk Lymphoma. 2019 Jul;60(7):1626-1631
pubmed: 30997845
Nature. 2012 Jan 11;481(7380):157-63
pubmed: 22237106
Stem Cells. 2014 Jul;32(7):1878-89
pubmed: 24677703
Int J Cancer. 2017 Sep 1;141(5):877-886
pubmed: 28597939